FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2289807654> ?p ?o ?g. }

• W2289807654 endingPage "e0149661" @default.
• W2289807654 startingPage "e0149661" @default.
• W2289807654 abstract "Background Triple-negative breast cancer (TNBC) is highly diverse group of cancers, and generally considered an aggressive disease associated with poor survival. Stratification of TNBC is highly desired for both prognosis and treatment decisions to identify patients who may benefit from less aggressive therapy. Methods This study retrieved 192 consecutive non-metastasis TNBC patients who had undergone a resection of a primary tumor from 2008 to 2012. All samples were negative for ER, PR, and HER2/neu. Disease-free-survival (DFS) and overall-survival (OS) were evaluated for expression of immunohistochemical biomarkers (P53, Ki-67, CK5/6 and EGFR), as well as clinicopathological variables including age, tumor size, grade, lymph node status, pathologic tumor and nodal stages. The cutoff values of the basal biomarkers, EGFR and CK5/6, were estimated by time-dependent ROC curves. The prognostic values of combinatorial variables were identified by univariate and multivariate Cox analysis. Patients were stratified into different risk groups based on expression status of identified prognostic variables. Results Median age was 57 years (range, 28–92 years). Patients’ tumor stage and nodal stage were significantly associated with OS and DFS. EGFR and CK5/6 were significant prognostic variables at cutoff points of 15% (p = 0.001, AUC = 0.723), and 50% (p = 0.006, AUC = 0.675), respectively. Multivariate Cox analysis identified five significant variables: EGFR (p = 0.016), CK5/6 (p = 0.018), Ki-67 (p = 0.048), tumor stage (p = 0.010), and nodal stage (p = 0.003). Patients were stratified into low basal (EGFR≤15% and CK5/6≤50%) and high basal (EGFR>15% and/or CK5/6>50%) expression groups. In the low basal expression group, patients with low expressions of Ki-67, low tumor and nodal stage had significantly better survival than those with high expressions/stages of three variables, log-rank p = 0.015 (100% vs 68% at 50 months). In the high basal expression group, patient with high basal expression of both biomarkers (EGFR >15% and CK5/6 >50%) had worse survival (mean DFS = 25 months, 41.7% event rate) than those patient with high expression of either one marker (mean DFS = 34 months, 25.5% event rate). Conclusions Immunoexpression of basal biomarkers, EGFR and CK5/6, is useful in predicting survival of TNBC patients. Integrated with Ki-67, tumor and nodal stages, combinatorial biomarker analysis provides a feasible clinical solution to stratify patient risks and help clinical decision-making with respect to selecting the appropriate therapies for individual patients." @default.
• W2289807654 created "2016-06-24" @default.
• W2289807654 creator A5002318539 @default.
• W2289807654 creator A5018298330 @default.
• W2289807654 creator A5028747924 @default.
• W2289807654 creator A5062083547 @default.
• W2289807654 creator A5062695905 @default.
• W2289807654 creator A5090256693 @default.
• W2289807654 date "2016-03-01" @default.
• W2289807654 modified "2023-10-17" @default.
• W2289807654 title "Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers" @default.
• W2289807654 cites W1970453414 @default.
• W2289807654 cites W1973709488 @default.
• W2289807654 cites W1986989859 @default.
• W2289807654 cites W1989938935 @default.
• W2289807654 cites W1992387129 @default.
• W2289807654 cites W1994068513 @default.
• W2289807654 cites W2044702943 @default.
• W2289807654 cites W2050522614 @default.
• W2289807654 cites W2063804661 @default.
• W2289807654 cites W2070480410 @default.
• W2289807654 cites W2081562657 @default.
• W2289807654 cites W2081772067 @default.
• W2289807654 cites W2088656245 @default.
• W2289807654 cites W2096864872 @default.
• W2289807654 cites W2102596641 @default.
• W2289807654 cites W2114586150 @default.
• W2289807654 cites W2125094267 @default.
• W2289807654 cites W2129067399 @default.
• W2289807654 cites W2135032122 @default.
• W2289807654 cites W2141572172 @default.
• W2289807654 cites W2142635246 @default.
• W2289807654 cites W2150524410 @default.
• W2289807654 cites W2153206149 @default.
• W2289807654 cites W2186272484 @default.
• W2289807654 doi "https://doi.org/10.1371/journal.pone.0149661" @default.
• W2289807654 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4773063" @default.
• W2289807654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26930401" @default.
• W2289807654 hasPublicationYear "2016" @default.
• W2289807654 type Work @default.
• W2289807654 sameAs 2289807654 @default.
• W2289807654 citedByCount "23" @default.
• W2289807654 countsByYear W22898076542017 @default.
• W2289807654 countsByYear W22898076542018 @default.
• W2289807654 countsByYear W22898076542019 @default.
• W2289807654 countsByYear W22898076542020 @default.
• W2289807654 countsByYear W22898076542021 @default.
• W2289807654 countsByYear W22898076542022 @default.
• W2289807654 countsByYear W22898076542023 @default.
• W2289807654 crossrefType "journal-article" @default.
• W2289807654 hasAuthorship W2289807654A5002318539 @default.
• W2289807654 hasAuthorship W2289807654A5018298330 @default.
• W2289807654 hasAuthorship W2289807654A5028747924 @default.
• W2289807654 hasAuthorship W2289807654A5062083547 @default.
• W2289807654 hasAuthorship W2289807654A5062695905 @default.
• W2289807654 hasAuthorship W2289807654A5090256693 @default.
• W2289807654 hasBestOaLocation W22898076541 @default.
• W2289807654 hasConcept C121608353 @default.
• W2289807654 hasConcept C126322002 @default.
• W2289807654 hasConcept C143998085 @default.
• W2289807654 hasConcept C144301174 @default.
• W2289807654 hasConcept C146357865 @default.
• W2289807654 hasConcept C151730666 @default.
• W2289807654 hasConcept C204232928 @default.
• W2289807654 hasConcept C2780110267 @default.
• W2289807654 hasConcept C2780849966 @default.
• W2289807654 hasConcept C38180746 @default.
• W2289807654 hasConcept C50382708 @default.
• W2289807654 hasConcept C530470458 @default.
• W2289807654 hasConcept C71924100 @default.
• W2289807654 hasConcept C86803240 @default.
• W2289807654 hasConceptScore W2289807654C121608353 @default.
• W2289807654 hasConceptScore W2289807654C126322002 @default.
• W2289807654 hasConceptScore W2289807654C143998085 @default.
• W2289807654 hasConceptScore W2289807654C144301174 @default.
• W2289807654 hasConceptScore W2289807654C146357865 @default.
• W2289807654 hasConceptScore W2289807654C151730666 @default.
• W2289807654 hasConceptScore W2289807654C204232928 @default.
• W2289807654 hasConceptScore W2289807654C2780110267 @default.
• W2289807654 hasConceptScore W2289807654C2780849966 @default.
• W2289807654 hasConceptScore W2289807654C38180746 @default.
• W2289807654 hasConceptScore W2289807654C50382708 @default.
• W2289807654 hasConceptScore W2289807654C530470458 @default.
• W2289807654 hasConceptScore W2289807654C71924100 @default.
• W2289807654 hasConceptScore W2289807654C86803240 @default.
• W2289807654 hasIssue "3" @default.
• W2289807654 hasLocation W22898076541 @default.
• W2289807654 hasLocation W22898076542 @default.
• W2289807654 hasLocation W22898076543 @default.
• W2289807654 hasLocation W22898076544 @default.
• W2289807654 hasOpenAccess W2289807654 @default.
• W2289807654 hasPrimaryLocation W22898076541 @default.
• W2289807654 hasRelatedWork W1905605175 @default.
• W2289807654 hasRelatedWork W2013102863 @default.
• W2289807654 hasRelatedWork W2025438229 @default.
• W2289807654 hasRelatedWork W2048873934 @default.
• W2289807654 hasRelatedWork W2361700749 @default.
• W2289807654 hasRelatedWork W2361948491 @default.

• next